Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024

Dr. Pinkal Desai (Weill Cornell Medical College, New York, NY, USA) presents her top abstracts from the 66th ASH Annual Meeting & Exposition on 7–10 December 2024 in San Diego, CA, USA. In this video she focusses on intensifying chemotherapy through combination therapy and menin inhibitors. These new therapies present an exciting potential to change the standard of care in the future for patients with acute myeloid leukaemia, but Dr. Desai emphasizes the need for larger, randomized studies to validate the findings from recent clinical trials and ensure long-term efficacy.

The abstracts she highlights are below:

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007 (1.20)

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results (3.30)

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine (4.30)

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML (6.20)

View more from Dr Desai, presenting the counter argument: Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024

Disclosures: Pinkal Desai has received grant/research support from: Kura Oncology, Janssen Research and BMS. she has been a member of the advisory board for: BMS, Kura Oncology, Syndax, Servier and Abbvie. She has received other financial or material support from Genentech/Roche.

This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. It is not affiliated with the American Society of Hematology (ASH). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.